Thermo Fisher Scientific Inc. $TMO Shares Sold by Pallas Capital Advisors LLC

Key Points

• Pallas Capital Advisors LLC significantly reduced its stake in Thermo Fisher Scientific Inc. by 83.4%, owning 2,090 shares valued at $847,000 after selling 10,535 shares during the 2nd quarter.
• Analysts are generally optimistic about Thermo Fisher Scientific, with 16 analysts giving a Buy rating and an average target price of $588.35.
• The company declared a quarterly dividend of $0.43 per share, with a payout ratio of 9.95%, further emphasizing its solid financial positioning.

Pallas Capital Advisors LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 83.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,090 shares of the medical research company's stock after selling 10,535 shares during the quarter. Pallas Capital Advisors LLC's holdings in Thermo Fisher Scientific were worth $847,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Thermo Fisher Scientific by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after acquiring an additional 230,382 shares during the last quarter. Amundi increased its stake in Thermo Fisher Scientific by 5.9% during the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after acquiring an additional 168,197 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after acquiring an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA increased its stake in Thermo Fisher Scientific by 7.2% during the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after acquiring an additional 193,378 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after acquiring an additional 329,974 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on TMO. HSBC restated a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Robert W. Baird boosted their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Finally, Barclays upgraded Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $490.00 to $550.00 in a research report on Thursday, September 11th. Sixteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $588.35.

Thermo Fisher Scientific Stock Performance

TMO traded down $1.08 during midday trading on Friday, hitting $480.02. 4,241,401 shares of the company were exchanged, compared to its average volume of 1,433,914. The company's 50 day simple moving average is $472.01 and its 200 day simple moving average is $449.50. The firm has a market capitalization of $181.26 billion, a price-to-earnings ratio of 27.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.75. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 in the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.